Media ReleasesArovella Therapeutics

View All Arovella Therapeutics News

Arovella Therapeutics - R&D Tax Incentive refund received

MELBOURNE, AUSTRALIA 29 NOVEMBER 2022: Arovella Therapeutics Limited (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform, is  leased to advise that it has received a refund of $1,048,763 from the Australian Taxation Office under the R&D Tax Incentive for the 2022 financial year.

The incentive recognises the research and development activities undertaken by Arovella during the last financial year. The receipt of $1.05m in additional funding will further support Arovella’s development work for the current year.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?